Awardee OrganizationRUSH UNIVERSITY MEDICAL CENTER
Description
Abstract Text
DESCRIPTION: (Adapted from Abstract) Mannan-binding lectin (MBL) is an effector
molecule of the innate immune system found in human serum that binds to
carbohydrate and mediates recognition and killing of pathogens. Although the
human immunodeficiency virus (HIV) would appear to be a good target of MBL due
the unusually high level of high mannose glycosylation of gpl20, this has not
been well studied. Our research - group found that MBL binds to a wide range of
HIV isolates including primary isolates. Thus, MBL has several highly desirable
features of an anti-HIV effector molecule; 1) it binds to a wide range of virus
isolates; 2) binding of MBL to HIV is likely via the unusual cluster of high
mannose microgram levels. These features of MBL suggest it mediates anti-viral
activity in vivo and inforrnation gained about its interaction with HIV will
lead to a better understanding of both the role of innate immunity during HIV
infection and the importance of carbohydrate structures on HIV. The overall
goals of this study are to determine the mechanism of interaction between MBL
and HIV and to determine methods to enhance the anti-HIV activity of MBL. These
goals will be accomplished by the following specific aims: Deterrnine the type
and location of carbobydrates responsible for high-level binding of HIV- 1 to
MBL. 2. Investigate factors that affect the interaction between HIV and MBL. 3.
Utilize inhibitors of glycosylation to enhance biological effects of MBL.
Exarnine the interaction of MBL with anti-viral antibodies in mediating
anti-viral effects. Deterrnine the interaction of HIV-1 with MBL in vivo.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
antiviral antibodyglycosylationhuman immunodeficiency virus 1human subjectlectinmannansphysical chemical interaction
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
068610245
UEI
C155UU2TXCP3
Project Start Date
01-August-2000
Project End Date
31-July-2004
Budget Start Date
01-August-2001
Budget End Date
31-July-2002
Project Funding Information for 2001
Total Funding
$250,250
Direct Costs
$175,000
Indirect Costs
$75,250
Year
Funding IC
FY Total Cost by IC
2001
National Institute of Allergy and Infectious Diseases
$250,250
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI046963-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI046963-02
Patents
No Patents information available for 5R01AI046963-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI046963-02
Clinical Studies
No Clinical Studies information available for 5R01AI046963-02
News and More
Related News Releases
No news release information available for 5R01AI046963-02
History
No Historical information available for 5R01AI046963-02
Similar Projects
No Similar Projects information available for 5R01AI046963-02